|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4195 EUR | +0.36% |
|
+2.32% | -8.80% |
| Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
| Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
GenSight Biologics S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 3 million compared to EUR 4.9 million a year ago. Net loss was EUR 26.2 million compared to EUR 27.6 million a year ago.
Basic loss per share from continuing operations was EUR 0.54 compared to EUR 0.6 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.80% | 34.94M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
GENSIGHT BIOLOGICS S.A. 
